Incretin-based therapies in type 2 diabetes: A review of clinical results

被引：20
|
作者：
Bosi, Emanuele [1 ]
Lucotti, Pietro
Setola, Emanuela
Monti, Lucilla
Piatti, Pier Marco
机构：
[1] Ist Sci San Raffaele, Diabet & Endocrinol Unit, Dept Internal Med, I-20132 Milan, Italy
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2008年 / 82卷
关键词：
GLP-1; analogues; DPP-4; inhibitors; Exenatide; Sitagliptin; Vidagliptin; Diabetes mellitus;
D O I：
10.1016/j.diabres.2008.10.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：S102 / S107
页数：6
相关论文
共 50 条
12345